Thus, anti‐PD‐1 or anti‐PD‐L1 antibodies activate CTLs by inhibiting this binding in the tumor microenvironment.3 Compared to existing chemotherapies, anti‐PD‐1 antibody significantly prolonged the overall survival of patients with untreated advanced non‐small cell lung cancer.4 Here, CD274 is linked to neoplasm.